Procalcitonin in Cirrhotic Patients at High Risk for Sepsis

Prof. Facchinetti Fabio75 enrolled

Overview

Infections are frequent life-threatening events in patients with cirrhosis, occurring at least in 35% of hospitalized patients and accounting for 20% of inpatients death. Among cirrhotics, ascitic patients have the highest risk of death for sepsis. At the admission, no clear-cut clinical and biochemical features are helpful in diagnosing and prognostically stratifying those patients with sepsis. Procalcitonin (PCT)is a breakthrough marker presenting high sensibility and specificity in diagnosing bacterial infections in different clinical settings. The purpose of this study is to evaluate PCT as a diagnostic and prognostic tool for sepsis in hospitalized cirrhotic patients with ascitic decompensation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cirrhosis Ascites Sepsis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * liver cirrhosis regardless of aetiology * clinically relevant ascitic decompensation at time of hospital admission Exclusion Criteria: * high haematic ascites * ongoing antimicrobial therapy or stopped less than 7 days before admission * last hospital discharge within 7 days * surgery or trauma within 30 days from enrolment * hepatocellular carcinoma out of Milan criteria * extra hepatic malignancies * immunodeficiency syndrome * pregnancy

Procalcitonin in Cirrhotic Patients at High Risk for Sepsis

Overview

Conditions

Eligibility

Locations (1)